Compare FTAIM & KTTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
FTAI Aviation Ltd. 9.500% Fixed-Rate Reset Series D Cumulative Perpetual Redeemable Preferred Shares
Current Price
Current Price
| Metric | FTAIM | KTTA |
|---|---|---|
| Founded | N/A | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Misc Corporate Leasing Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | N/A | 18.1M |
| IPO Year | 2014 | 2021 |
| Metric | FTAIM | KTTA |
|---|---|---|
| Price | $27.12 | $0.52 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 1.3K | ★ 214.9K |
| Earning Date | N/A | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 1537.50 | 77.07 |
| EPS | ★ 2.42 | N/A |
| Revenue | ★ $2,507,409,000.00 | $486,559.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $11.20 | ★ N/A |
| Revenue Growth | 44.53 | ★ 3130.37 |
| 52 Week Low | $26.31 | $0.28 |
| 52 Week High | $27.81 | $2.06 |
| Indicator | FTAIM | KTTA |
|---|---|---|
| Relative Strength Index (RSI) | 39.47 | 47.80 |
| Support Level | $26.85 | $0.48 |
| Resistance Level | $27.39 | $0.52 |
| Average True Range (ATR) | 0.08 | 0.04 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 22.50 | 34.21 |
FTAI Aviation Ltd is an independent engine maintenance platform focused on the CFM56-5B, CFM56-7B, and V2500 aircraft engines, which power the 737NG and A320ceo aircraft. The company repairs and rebuilds engines in its maintenance facilities and with joint venture partners, and sells or leases engines through its proprietary Maintenance, Repair and Exchange (MRE) model under the Aerospace Products segment, which earns maximum revenue from North America and develops, repairs/refurbishes, and sells aircraft engines and aftermarket components. It also operates an Aviation Leasing segment, owning and managing a portfolio of on- and off-lease aircraft and engines, including engine transfers for rebuilding and sales.
Pasithea Therapeutics Corp is a biotechnology company. It is focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers. It leveraging in the fields of neuroscience, translational medicine, and drug development. The disorders covered includes Neurofibromatosis Type 1, Amyotrophic Lateral Sclerosis (ALS), Multiple Sclerosis (MS), and Schizophrenia. Companies pipelines includes PAS-004 (Macrocyclic Small Module[MEK1/2]), PAS-003 (Monoclonal antibody),PAS-001 (Small Module). The Company has reportable segment, which is the business of research and development of treatments for central nervous system (CNS) disorders and other diseases, including RASopathies and certain cancers.